<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moreno, Anna Camille</style></author><author><style face="normal" font="default" size="100%">Sikka, Sabrina K.</style></author><author><style face="normal" font="default" size="100%">Thacker, Holly L.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Genitourinary syndrome of menopause in breast cancer survivors: Treatments are available</style></title><secondary-title><style face="normal" font="default" size="100%">Cleveland Clinic Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">760-766</style></pages><doi><style  face="normal" font="default" size="100%">10.3949/ccjm.85a.17108</style></doi><volume><style face="normal" font="default" size="100%">85</style></volume><issue><style face="normal" font="default" size="100%">10</style></issue><abstract><style  face="normal" font="default" size="100%">When treating the genitourinary syndrome of menopause (GSM) in women with breast cancer or at high risk of breast cancer, clinicians must balance the higher cancer risks associated with hormonal treatments against the severity of GSM symptoms, which can be exacerbated by breast cancer treatments. Options for patients who need hormonal therapy include locally applied estrogens, dehydroepiandrosterone (DHEA), and estrogen receptor agonists/antagonists, which vary in their impact on breast cancer risk.</style></abstract></record></records></xml>